PMID- 37153592 OWN - NLM STAT- MEDLINE DCOM- 20230509 LR - 20230509 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - The first successful bone marrow transplantation in Vietnam for a young Vietnamese boy with chronic granulomatous disease: a case report. PG - 1134852 LID - 10.3389/fimmu.2023.1134852 [doi] LID - 1134852 AB - BACKGROUND: Chronic granulomatous disease (CGD) is an inborn error of immunity (IEI) disorder that results from defects in the respiratory burst activity in phagocytes, leading to the inability to kill bacterial and fungal microorganisms. CGD patients usually have a high incidence of morbidity such as infections and autoinflammatory diseases and a high mortality rate. Allogeneic bone marrow transplantation (BMT) is the only definitive cure for patients who suffer from CGD. CASE PRESENTATION: We report the first transplant case of chronic granulomatous disease in Vietnam. A 25-month-old boy with X-linked CGD underwent bone marrow transplantation from his 5-year-old, full-matched human leukocyte antigen (HLA)-carrier sibling after myeloablative conditioning regimen with busulfan 5.1 mg/kg/day for 4 days, fludarabine 30 mg/m(2)/day for 5 days, and rATG (Grafalon-Fresenius) 10 mg/kg/day for 4 days. Neutrophil was engrafted on day 13 posttransplant, donor chimerism was 100% on day 30 with the dihydrorhodamine-1,2,3 (DHR 123) flow cytometric assay test that reached 38% of the normal 45 days posttransplant. Five months after transplant, the patient was free of infection with stable DHR 123 assay at 37%, and donor chimerism remained 100%. No sign of a graft-versus-host disease had been observed posttransplant. CONCLUSION: We suggest that bone marrow transplantation is a safe and effectual cure for CGD patients, especially for patients with HLA-identical siblings. CI - Copyright (c) 2023 Nguyen-Thanh, Nguyen-Ngoc-Quynh, Dang-Thi, Le-Quynh, Nguyen-Thi-Van, Thuc-Thanh, Dang-Anh, Lee, Cao-Viet and Tran-Minh. FAU - Nguyen-Thanh, Binh AU - Nguyen-Thanh B AD - Stem Cells Center, Vietnam National Children's Hospital, Hanoi, Vietnam. AD - Pathophysiology and Immunology Department, Hanoi Medical University, Hanoi, Vietnam. FAU - Nguyen-Ngoc-Quynh, Le AU - Nguyen-Ngoc-Quynh L AD - Stem Cells Center, Vietnam National Children's Hospital, Hanoi, Vietnam. FAU - Dang-Thi, Ha AU - Dang-Thi H AD - Stem Cells Center, Vietnam National Children's Hospital, Hanoi, Vietnam. FAU - Le-Quynh, Chi AU - Le-Quynh C AD - Department of Rheumatology, Allergy, and Immunology, Vietnam National Children's Hospital, Hanoi, Vietnam. FAU - Nguyen-Thi-Van, Anh AU - Nguyen-Thi-Van A AD - Department of Rheumatology, Allergy, and Immunology, Vietnam National Children's Hospital, Hanoi, Vietnam. FAU - Thuc-Thanh, Huyen AU - Thuc-Thanh H AD - Department of Rheumatology, Allergy, and Immunology, Vietnam National Children's Hospital, Hanoi, Vietnam. FAU - Dang-Anh, Duong AU - Dang-Anh D AD - Surgical Intensive Care Unit, Vietnam National Children's Hospital, Hanoi, Vietnam. FAU - Lee, Pamela P AU - Lee PP AD - Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. FAU - Cao-Viet, Tung AU - Cao-Viet T AD - Children Heart Center, National Children's Hospital, Hanoi, Vietnam. FAU - Tran-Minh, Dien AU - Tran-Minh D AD - Surgical Intensive Care Unit, Vietnam National Children's Hospital, Hanoi, Vietnam. LA - eng PT - Case Reports DEP - 20230420 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 SB - IM MH - Male MH - Humans MH - Child, Preschool MH - Bone Marrow Transplantation MH - *Granulomatous Disease, Chronic/therapy MH - Vietnam MH - Southeast Asian People MH - *Hematopoietic Stem Cell Transplantation/methods PMC - PMC10156979 OTO - NOTNLM OT - Chronic granulomatous disease OT - Vietnam OT - bone marrow transplant OT - case report OT - inborn error of immunity COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/05/08 06:41 MHDA- 2023/05/09 06:42 PMCR- 2023/01/01 CRDT- 2023/05/08 04:17 PHST- 2022/12/31 00:00 [received] PHST- 2023/04/03 00:00 [accepted] PHST- 2023/05/09 06:42 [medline] PHST- 2023/05/08 06:41 [pubmed] PHST- 2023/05/08 04:17 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1134852 [doi] PST - epublish SO - Front Immunol. 2023 Apr 20;14:1134852. doi: 10.3389/fimmu.2023.1134852. eCollection 2023.